However, in a larger phase 3 trial of 24 weeks duration no difference was found from placebo in the Alzheimer’s disease assessment scale in those with or without an ApoE4 gene with doses of two and eight mg of Rosiglitazone (Gold et al., 2010). This evidence concerns the gene APOE and Alzheimer disease.